Fulcrum Therapeutics, Inc. (FULC) saw its stock plummet by over 60% after its phase III REACH study for losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD) failed to meet its primary endpoint. While this news is a setback for the company, Fulcrum remains focused on its other pipeline candidate, pociredir, for sickle cell disease, which has garnered significant attention and potential.